ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 232 filers reported holding ACADIA PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.85 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,633,412 | -14.3% | 174,348 | -1.5% | 0.27% | -8.3% |
| Q2 2023 | $4,240,635 | +126827.1% | 177,062 | -0.3% | 0.29% | +21.8% |
| Q1 2023 | $3,341 | +19.4% | 177,523 | +1.0% | 0.24% | +24.0% |
| Q4 2022 | $2,799 | -99.9% | 175,841 | -1.1% | 0.19% | -13.1% |
| Q3 2022 | $2,910,000 | +20.1% | 177,852 | +3.4% | 0.22% | +26.3% |
| Q2 2022 | $2,422,000 | -40.7% | 171,922 | +2.0% | 0.18% | -33.2% |
| Q1 2022 | $4,084,000 | +4.0% | 168,621 | +0.2% | 0.26% | +9.6% |
| Q4 2021 | $3,928,000 | +40.8% | 168,276 | +0.2% | 0.24% | +30.6% |
| Q3 2021 | $2,790,000 | -31.1% | 167,953 | +1.2% | 0.18% | -29.6% |
| Q2 2021 | $4,048,000 | -2.4% | 165,965 | +3.2% | 0.26% | -8.8% |
| Q1 2021 | $4,149,000 | +46.3% | 160,818 | +203.2% | 0.28% | +42.5% |
| Q4 2020 | $2,836,000 | +125.3% | 53,046 | +73.8% | 0.20% | +98.0% |
| Q3 2020 | $1,259,000 | – | 30,526 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 432,317 | $11,154,000 | 4.70% |
| Baker Brothers Advisors | 41,910,704 | $1,081,296,000 | 4.69% |
| Palo Alto Investors LP | 2,337,877 | $60,317,000 | 3.44% |
| Birchview Capital, LP | 177,000 | $4,567,000 | 2.71% |
| Longitude (Cayman) Ltd. | 188,000 | $4,850,000 | 1.86% |
| GREAT POINT PARTNERS LLC | 311,217 | $8,029,000 | 1.66% |
| Avoro Capital Advisors LLC | 2,500,000 | $64,500,000 | 1.11% |
| PFM Health Sciences, LP | 1,302,129 | $33,595,000 | 1.03% |
| HealthCor Management, L.P. | 900,490 | $23,233,000 | 0.82% |
| Eversept Partners, LP | 420,000 | $10,836,000 | 0.82% |